Survival for glucagonoma

Glucagonoma is a type of neuroendocrine tumour (NET) of the pancreas. Survival for glucagonomas depends on many factors. So you should only use these statistics as a guide.

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Because glucagonomas are rare tumours, the survival of this disease is harder to estimate than for other, more common cancers.

These are general statistics based on small groups of people. Remember, they can’t tell you what will happen in your individual case. Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

What affects survival

Survival depends on many factors. It depends on the stage and grade of the tumour when it was diagnosed. The stage describes the size of the tumour and whether it has spread. The grade means how abnormal the cells look under a microscope.

Another factor is how well you are overall. 

Survival for glucagonomas

There are no UK survival statistics for the different types of NETs. The statistics below are from an international study. Please be aware that due to differences in health care systems, data collection and the population, these figures may not be a true picture of survival in the UK.

Most people with a glucagonoma that hasn't spread to other parts of the body have surgery to try to cure their cancer. About 64 out of every 100 people (64%) with glucagonoma that has not spread to other parts of the body survive for 10 years or more. 

Almost 52 out of every 100 people (52%) with glucagonoma that has spread to other parts of the body survive for 10 years or more.

Survival for NETs of the pancreas

In the UK, no statistics are available for the survival of all the different types of pancreatic NETs. This is because researchers haven’t collected this information yet. The information we have here is the 1 year survival for all types of pancreatic NETs.

This information is from people diagnosed in England between 2013-2015. Because this is for England only, it might not be the same for the whole of the UK.

Around 80 out of every 100 people (80%) diagnosed with a pancreatic NET survive for 1 year or more. 

About these statistics

The term 1 year, 5 year and 10 year survival does not mean that you will only live for 1, 5 or 10 years. They relate to the number of people who are still alive 1 year, 5 years or 10 years after their diagnosis.

Some people live much longer than 10 years.

What next?

You might want to read our information about treatment for glucagonomas. 

Last reviewed: 
25 Jun 2019
  • Functioning and nonfunctioning pNENs
    K Daskalakis 
    Current Opinion in Endocrine and Metabolic Research, 2021. Vol 18, June 2021, Pages 284-290

  • Glucagonomas/diabetic-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases
    Jun Soja and Yasuko Yakuwa
    Journal of Hepatobiliary Pancreatic Surgery, 1998. Vol 5, Pages 312-319

  • 1-Year survival rates for neuroendocrine tumour patients in England
    T Genus and others
    Public Health England, 2017

  • Neuroendocrine Tumours: Diagnosis and Management
    S Yalcin and K Oberg
    Springer, 2015

  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
    T Halfdanarson and others
    Annals of Oncology, 2008. Vol 19, Pages 1727-1733

  • ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes
    R T Jensen and others
    Neuroendocrinology, 2012. Vol 95, Pages 98-119

Related links